DE69330351T2 - 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten - Google Patents

5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten

Info

Publication number
DE69330351T2
DE69330351T2 DE69330351T DE69330351T DE69330351T2 DE 69330351 T2 DE69330351 T2 DE 69330351T2 DE 69330351 T DE69330351 T DE 69330351T DE 69330351 T DE69330351 T DE 69330351T DE 69330351 T2 DE69330351 T2 DE 69330351T2
Authority
DE
Germany
Prior art keywords
ylmethyl
indol
benzimidazole
alkyl
methylpyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330351T
Other languages
German (de)
English (en)
Other versions
DE69330351D1 (de
Inventor
Eugene Macor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Inc filed Critical Pfizer Corp Belgium
Publication of DE69330351D1 publication Critical patent/DE69330351D1/de
Application granted granted Critical
Publication of DE69330351T2 publication Critical patent/DE69330351T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DE69330351T 1992-11-02 1993-10-19 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten Expired - Fee Related DE69330351T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
PCT/US1993/009790 WO1994010171A1 (en) 1992-11-02 1993-10-19 5-arylindole derivatives and their use as serotonin (5-ht1) agonists

Publications (2)

Publication Number Publication Date
DE69330351D1 DE69330351D1 (de) 2001-07-19
DE69330351T2 true DE69330351T2 (de) 2001-09-20

Family

ID=25517470

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330351T Expired - Fee Related DE69330351T2 (de) 1992-11-02 1993-10-19 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten

Country Status (27)

Country Link
US (1) US5886008A (enExample)
EP (2) EP1094064A1 (enExample)
JP (1) JP2788551B2 (enExample)
KR (1) KR0163371B1 (enExample)
CN (1) CN1051313C (enExample)
AT (1) ATE202102T1 (enExample)
AU (1) AU685066B2 (enExample)
BR (1) BR9307348A (enExample)
CA (2) CA2148380C (enExample)
CZ (1) CZ283001B6 (enExample)
DE (1) DE69330351T2 (enExample)
DK (1) DK0666858T3 (enExample)
EG (1) EG20396A (enExample)
ES (1) ES2157224T3 (enExample)
FI (2) FI111257B (enExample)
GR (1) GR3036579T3 (enExample)
HU (1) HU222235B1 (enExample)
IL (1) IL107386A (enExample)
MY (1) MY109696A (enExample)
NO (1) NO309652B1 (enExample)
NZ (1) NZ257059A (enExample)
PL (1) PL176091B1 (enExample)
PT (1) PT666858E (enExample)
RU (1) RU2134266C1 (enExample)
TW (1) TW251284B (enExample)
WO (1) WO1994010171A1 (enExample)
ZA (1) ZA938137B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
DK0716649T3 (da) * 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater
CN1067386C (zh) * 1994-02-10 2001-06-20 辉瑞大药厂 作为苯并二氮杂䓬受体位的兴奋剂和拮抗药的5－杂芳基吲哚衍生物
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
WO1996029075A1 (en) * 1995-03-20 1996-09-26 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
AU7261196A (en) * 1995-10-10 1997-04-30 Eli Lilly And Company N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists
IL133800A0 (en) 1997-07-03 2001-04-30 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
EP1558586B1 (en) 2002-10-30 2011-03-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
KR20060119871A (ko) * 2003-08-21 2006-11-24 오에스아이 파마슈티컬스, 인코포레이티드 Ｎ３―치환된 이미다조피리딘 ｃ―ｋｉｔ 억제제
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
WO2005032484A2 (en) 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
RU2434863C2 (ru) * 2006-03-22 2011-11-27 Янссен Фармацевтика Н.В. Производные циклических алкиламинов в качестве ингибиторов взаимодействия между mdm2 и р53
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
ES2881081T3 (es) 2013-03-15 2021-11-26 Agenebio Inc Procedimientos y composiciones para mejorar la función cognitiva
ES2759348T3 (es) 2015-04-29 2020-05-08 Janssen Pharmaceutica Nv Imidazopirazinas y pirazolopirimidinas y su utilización como moduladores de receptores AMPA
CN107635970B (zh) 2015-04-29 2021-03-12 詹森药业有限公司 苯并咪唑酮和苯并噻唑酮化合物以及它们作为ampa受体调节剂的用途
UY36654A (es) 2015-04-29 2016-10-31 Janssen Pharmaceutica Nv Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
KR20170141769A (ko) 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 인돌론 화합물 및 ampa 수용체 조절제로서의 이의 용도
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2017076931A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
JP6839184B2 (ja) 2015-11-06 2021-03-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インドリン−２−オン誘導体
AU2016348493B2 (en) 2015-11-06 2021-02-25 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
CN108137555B (zh) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 可用于治疗cns疾病的二氢吲哚-2-酮衍生物
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
MC2210A1 (fr) * 1990-06-07 1992-11-26 Wellcome Found Composes heterocycliques therapeutiques,leur utilisation et procede pour les preparer
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
ES2104733T3 (es) * 1990-10-15 1997-10-16 Pfizer Derivados de indol.
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
EP1094064A1 (en) 2001-04-25
ATE202102T1 (de) 2001-06-15
NO951633D0 (no) 1995-04-28
AU685066B2 (en) 1998-01-15
FI20002505A7 (fi) 2000-11-15
JP2788551B2 (ja) 1998-08-20
ZA938137B (en) 1995-05-02
TW251284B (enExample) 1995-07-11
PT666858E (pt) 2001-09-28
KR0163371B1 (ko) 1998-12-01
FI20002505L (fi) 2000-11-15
RU2134266C1 (ru) 1999-08-10
CZ283001B6 (cs) 1997-12-17
HUT66011A (en) 1994-08-29
CA2340999A1 (en) 1994-05-11
CN1051313C (zh) 2000-04-12
CA2148380C (en) 2001-08-14
RU95109927A (ru) 1997-01-10
US5886008A (en) 1999-03-23
AU5329494A (en) 1994-05-24
EP0666858A1 (en) 1995-08-16
DK0666858T3 (da) 2001-08-27
PL308669A1 (en) 1995-08-21
DE69330351D1 (de) 2001-07-19
FI111257B (fi) 2003-06-30
IL107386A0 (en) 1994-01-25
NO309652B1 (no) 2001-03-05
CN1094727A (zh) 1994-11-09
FI934825A0 (fi) 1993-11-01
JPH07508759A (ja) 1995-09-28
PL176091B1 (pl) 1999-04-30
ES2157224T3 (es) 2001-08-16
NZ257059A (en) 1997-07-27
CZ110895A3 (en) 1995-11-15
HU222235B1 (hu) 2003-05-28
BR9307348A (pt) 1999-05-11
EP0666858B1 (en) 2001-06-13
IL107386A (en) 1999-03-12
GR3036579T3 (en) 2001-12-31
CA2340999C (en) 2005-01-04
CA2148380A1 (en) 1994-05-11
NO951633L (no) 1995-04-28
FI934825L (fi) 1994-05-03
WO1994010171A1 (en) 1994-05-11
EG20396A (en) 1999-02-28
KR950704313A (ko) 1995-11-17
MY109696A (en) 1997-04-30

Similar Documents

Publication Publication Date Title
DE69330351T2 (de) 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten
DE69230803T2 (de) 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
DE69413240T2 (de) 5-arylindolderivate
DE69132691T2 (de) Indolderivate als 5-HT1-like Agonisten
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
DE69127468T2 (de) Indolderivate
DE69331988T2 (de) Indol derivate als 5-ht1 agoniste
DE69028934T2 (de) Tetrahydrobenzimidazol-Derivate
DE69307875T2 (de) Acylaminoindolderivate als 5-ht1 agonisten
US5053511A (en) 1,3-dihydro-1-(pyridinylamino)-2h-indol-2-ones
DE69323667T2 (de) 4-substituierte 1,2,4-Triazolderivate
JPH07506825A (ja) ５−ｈｔ１レセプターアゴニストとしての縮合イミダゾール及びトリアゾール誘導体
NZ228721A (en) Substituted indoles and indazoles and pharmaceutical compositions
DE69221652T2 (de) Substituiertes cyclisches Sulfamidderivat
DE69329645T2 (de) Imidazol-, triazol- und tetrazolderivate
DE69425510T2 (de) 3-substituierte 1-arylindolverbindungen
DE69521295T2 (de) Triazolderivate
US5621116A (en) 1-amino-3,3-bis(thienylalkyl)-1,3-dihydro-2H-indol-2-ones
US5994352A (en) 5-arylindole derivatives
JPWO1993020077A1 (ja) 縮合キノキサリノン誘導体及びその医薬組成物

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee